BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

460 related articles for article (PubMed ID: 23664616)

  • 1. Excitatory/inhibitory synaptic imbalance leads to hippocampal hyperexcitability in mouse models of tuberous sclerosis.
    Bateup HS; Johnson CA; Denefrio CL; Saulnier JL; Kornacker K; Sabatini BL
    Neuron; 2013 May; 78(3):510-22. PubMed ID: 23664616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of tuberous sclerosis complex.
    Zeng LH; Rensing NR; Zhang B; Gutmann DH; Gambello MJ; Wong M
    Hum Mol Genet; 2011 Feb; 20(3):445-54. PubMed ID: 21062901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tuberous sclerosis complex activity is required to control neuronal stress responses in an mTOR-dependent manner.
    Di Nardo A; Kramvis I; Cho N; Sadowski A; Meikle L; Kwiatkowski DJ; Sahin M
    J Neurosci; 2009 May; 29(18):5926-37. PubMed ID: 19420259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vigabatrin inhibits seizures and mTOR pathway activation in a mouse model of tuberous sclerosis complex.
    Zhang B; McDaniel SS; Rensing NR; Wong M
    PLoS One; 2013; 8(2):e57445. PubMed ID: 23437388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impaired autophagy in neurons after disinhibition of mammalian target of rapamycin and its contribution to epileptogenesis.
    McMahon J; Huang X; Yang J; Komatsu M; Yue Z; Qian J; Zhu X; Huang Y
    J Neurosci; 2012 Nov; 32(45):15704-14. PubMed ID: 23136410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model.
    Mi R; Ma J; Zhang D; Li L; Zhang H
    J Genet Genomics; 2009 Jun; 36(6):355-61. PubMed ID: 19539245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of TSC1 and TSC2 proteins in neuronal axons.
    Karalis V; Wood D; Teaney NA; Sahin M
    Mol Psychiatry; 2024 Apr; 29(4):1165-1178. PubMed ID: 38212374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapamycin for treating Tuberous sclerosis and Autism spectrum disorders.
    Ehninger D; Silva AJ
    Trends Mol Med; 2011 Feb; 17(2):78-87. PubMed ID: 21115397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of YAP by mTOR and autophagy reveals a therapeutic target of tuberous sclerosis complex.
    Liang N; Zhang C; Dill P; Panasyuk G; Pion D; Koka V; Gallazzini M; Olson EN; Lam H; Henske EP; Dong Z; Apte U; Pallet N; Johnson RL; Terzi F; Kwiatkowski DJ; Scoazec JY; Martignoni G; Pende M
    J Exp Med; 2014 Oct; 211(11):2249-63. PubMed ID: 25288394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tuberous sclerosis complex.
    Hasbani DM; Crino PB
    Handb Clin Neurol; 2018; 148():813-822. PubMed ID: 29478616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-canonical functions of the tuberous sclerosis complex-Rheb signalling axis.
    Neuman NA; Henske EP
    EMBO Mol Med; 2011 Apr; 3(4):189-200. PubMed ID: 21412983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A circuitry and biochemical basis for tuberous sclerosis symptoms: from epilepsy to neurocognitive deficits.
    Feliciano DM; Lin TV; Hartman NW; Bartley CM; Kubera C; Hsieh L; Lafourcade C; O'Keefe RA; Bordey A
    Int J Dev Neurosci; 2013 Nov; 31(7):667-78. PubMed ID: 23485365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective suppression of excessive GluN2C expression rescues early epilepsy in a tuberous sclerosis murine model.
    Lozovaya N; Gataullina S; Tsintsadze T; Tsintsadze V; Pallesi-Pocachard E; Minlebaev M; Goriounova NA; Buhler E; Watrin F; Shityakov S; Becker AJ; Bordey A; Milh M; Scavarda D; Bulteau C; Dorfmuller G; Delalande O; Represa A; Cardoso C; Dulac O; Ben-Ari Y; Burnashev N
    Nat Commun; 2014 Aug; 5():4563. PubMed ID: 25081057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Linking tuberous sclerosis complex, excessive mTOR signaling, and age-related neurodegeneration: a new association between TSC1 mutation and frontotemporal dementia.
    Olney NT; Alquezar C; Ramos EM; Nana AL; Fong JC; Karydas AM; Taylor JB; Stephens ML; Argouarch AR; Van Berlo VA; Dokuru DR; Sherr EH; Jicha GA; Dillon WP; Desikan RS; De May M; Seeley WW; Coppola G; Miller BL; Kao AW
    Acta Neuropathol; 2017 Nov; 134(5):813-816. PubMed ID: 28828560
    [No Abstract]   [Full Text] [Related]  

  • 15. Complex Neurological Phenotype in Mutant Mice Lacking Tsc2 in Excitatory Neurons of the Developing Forebrain(123).
    Crowell B; Lee GH; Nikolaeva I; Dal Pozzo V; D'Arcangelo G
    eNeuro; 2015; 2(6):. PubMed ID: 26693177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperexcitability of the local cortical circuit in mouse models of tuberous sclerosis complex.
    Zhao JP; Yoshii A
    Mol Brain; 2019 Jan; 12(1):6. PubMed ID: 30683131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Stress-Induced Atf3-Gelsolin Cascade Underlies Dendritic Spine Deficits in Neuronal Models of Tuberous Sclerosis Complex.
    Nie D; Chen Z; Ebrahimi-Fakhari D; Di Nardo A; Julich K; Robson VK; Cheng YC; Woolf CJ; Heiman M; Sahin M
    J Neurosci; 2015 Jul; 35(30):10762-72. PubMed ID: 26224859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain Symptoms of Tuberous Sclerosis Complex: Pathogenesis and Treatment.
    Mizuguchi M; Ohsawa M; Kashii H; Sato A
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34206526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impaired astrocytic gap junction coupling and potassium buffering in a mouse model of tuberous sclerosis complex.
    Xu L; Zeng LH; Wong M
    Neurobiol Dis; 2009 May; 34(2):291-9. PubMed ID: 19385061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tuberous Sclerosis: A New Frontier in Targeted Treatment of Autism.
    Davis PE; Peters JM; Krueger DA; Sahin M
    Neurotherapeutics; 2015 Jul; 12(3):572-83. PubMed ID: 25986747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.